Among patients participating in the TIMI-II protocol, there was a variability in the fibrinolytic re sponse to recombinant tissue plasminogen activator (rt- PA). A cohort of 20 TIMI-II patients was selected for detailed study because their responses to rt-PA varied widely in the degree of fibrin(ogen)olysis. Patient plasmas were analyzed by immunoblotting for changes in fibrino gen and plasminogen. Measurements of fibrinogen, fibrin ogen degradation product (FDP), D-dimer, Bβ 1-42, plas minogen, and t-PA were also correlated. Three patterns of response to rt-PA were identified: Group A (n = 4) had fibrinogenolysis without fibrinolysis; Group B ( n = 11) had fibrinolysis and mild fibrinogenolysis; and Group C ( n = 5) had fibrinolysis with intense fibrinogenolysis. Group C patients also demonstrated qualitative changes in high- molecular-weight (HMW) and low-molecular-weight (LMW) fibrinogens, whereas Group A and B patients demonstrated only mild alterations in fibrinogen compo sition. Plasmin-inhibitor complexes were identified in all three groups. All patients had both plasmin-α2-anti plasmin and plasmin-α2-macroglobulin complexes at the 50-min time point. The concentration of pretreatment plasminogen correlated with the degree of fibrinogenoly sis.
Fletcher AP, Alkjaersig N., Smymiotis FE, et al. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians1958 ;71:287.
2.
DeWood MA, Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med1980;303:897.
3.
Rentrop P., Blanke H., Karsch KR, et al. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation1981;63:307.
4.
Spann JF, Sherry S., Carabello BA, et al. High-dose brief intravenous streptokinase early in acute myocardial infarction. Am Heart J1982;104:939.
5.
Little WC, Rogers EWAngiographic evidence of hemorrhagic myocardial infarction after intracoronary thrombolysis with streptokinase. Am J Cardiol1983;51:906.
6.
Rijken DC, Hoylaerts M., Collen D.Fibrinolytic properties of one-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem1982;257:2920.
7.
Hoylaerts M. , Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem1982;257:2912.
8.
Schielen Wjg , Adams Hphm, Boskuilen M., et al. The sequence of Aα-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen . Blood Coagul Fibrinolysis1991 ;2:465.
9.
Van de Werf F. , Ludbrook PA, Bergmann SR, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med1984;310:609.
10.
Collen D., Verstraete M.Systemic thrombolytic therapy of acute myocardial infarction? Circulation1983;68:462.
11.
Sobel BE, Gross RW, Robison AKThrombolysis, clot selectivity and kinetics. Circulation1984;70:160.
12.
Topol EJ, Bell WR, Weisfeldt MLCoronary thrombolysis with recombinant tissue type plasminogen activator . A hematologic and pharmacologic study. Ann Intern Med1985 ; 103:837.
13.
Owen J., Friedman KD, Grossman BA, et al. Quantitation of fragment X formation during thrombolytic therapy with streptokinase or tissue plasminogen activator. J Clin Invest1987 ;79:1642.
14.
Passamani E. , Hodges M., Herman M., et al. The thrombolysis in myocardial infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol1987;10: 51B.
15.
Lawler CM, Bovill EG, Stump DC, et al. Fibrin fragment D-dimer and fibrinogen Bβ peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction . Blood1990;76:1341.
16.
Clauss A.Gerinnungphysiologische Schnellmethode zur Bestimmung des Fibrinogens . Acta Haematol1957;17:237.
17.
Merskey C., Laezari P., Johnson AJA rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med1969 ;131:871.
18.
Holvoet P., Cleemput H., Collen D.Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost1985;54:684.
19.
Declerck PJ , Mombaerts P., Holvoet P., et al. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis . Thromb Haemost1987;58:1024.
20.
Towbin H., Staehlin T., Gordon J.Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA1979;76:4350.
21.
VandeWater L., Carr JM, Aronson D., et al. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease . Blood1986;67:1468.
22.
Carr JM, McKinney M., McDonagh J.Diagnosis of disseminated intravascular coagulation. Role of D-dimer . Am J Clin Pathol1989 ;91:280.
23.
Holm B., Godal HCQuantitation of the three normally occurring plasma fibrinogens in health and during so-called "acute phase" by SDS electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res1984 ;35:279.
24.
Lee P., Matsueda GR, Allen PMT-cell recognition of fibrinogen. A determinant on the Aα-chain does not require processing. J Immunol1988 ;140:1063.
25.
Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin and aspirin in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) Phase II trial . Ann Intern Med1991;115:256.
26.
Thorsen S., Mullertz S., Suenson E., et al. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J1984;223:179.
27.
Mills D., Karpatkin S.Heterogeneity of human fibrinogen: possible relation to proteolysis by thrombin and plasmin as studied by SDS-polyacrylamide gel electrophoresis . Biochem Biophys Res Commun1970;40:206.
28.
Holm B., Nilsen Dwt, Godal HCEvidence that low molecular fibrinogen (LMW) is formed in many by degradation of high molecular weight fibrinogen (HMW). Thromb Res1986; 41:879.
29.
Marder VJ, Shulman NR, Carroll WRHigh molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem1969;244:2111.
30.
Mirshahi M. , Soria J., Soria C., et al. Degradation of fibrinogen by tissue plasminogen activator. Consequences for fibrin polymerization . Thromb Res Suppl 1990;10:21.
31.
Thorsen LI, Holm B., Brosstad F., et al. Interactions of human blood platelets with three circulating plasma fibrinogens of different molecular weights. Thromb Res1987;47:683.
32.
Shen L., McDonagh RP, McDonagh J., et al. Early events in the plasmin digestion of fibrinogen and fibrin: effects of plasmin on fibrin polymerization. J Biol Chem1977;252:6184.
33.
Reganon E., Vila V., Aznar J., et al. Human fibrinogen heterogeneity. A study of limited fibrinogen degradation. Clin Chim Acta1989;184:7.
34.
Stump DC, Califf RM, Topol EJ, et al. Pharmacodynamics of thrombolysis with recombinant tissue type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation1989;80:1222.
35.
Collen D., Bonameaux H., De Cock F., et al. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation1986;73: 511.
36.
Robbins KCThe plasminogen-plasmin enzyme system. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis basic principles and clinical practice (2nd ed.) Philadelphia, PA : JB Lippincott, 1987:351.
37.
Nishino N., Kakkar VV, Scully MFInfluence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro. Thromb Haemost1991 ;66:672.
38.
Kaczmarek E. , Lee MH, McDonagh J.Initial interaction between fibrin and tissue plasminogen activator (t-PA). J Biol Chem1993;268:2474.
